MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 25.04.2026
Nymox Pharmaceutical Corporation Anteile 2011-2026 | NYMX
Anteile Jährlich Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 82 M | 73.8 M | 68.8 M | 60.5 M | 52.6 M | 46.2 M | 37.4 M | 35.3 M | 34.1 M | 33.2 M | 32.7 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 82 M | 32.7 M | 50.6 M |
Anteile Vierteljährlich Nymox Pharmaceutical Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 86 M | - | 83.8 M | 81.5 M | 78 M | - | 74.7 M | 71.7 M | 71.6 M | - | 70 M | 68.4 M | 67 M | - | 61.5 M | 59.3 M | 57.1 M | - | 53.3 M | 51.5 K | 49.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 86 M | 49.7 K | 61.5 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
38.7 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
4.73 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Coherus BioSciences
CHRS
|
117 M | $ 1.63 | - | $ 191 M | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
1.55 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
27.4 M | $ 7.83 | - | $ 214 M |  Israel |
 |
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
9.34 B | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
98.5 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
54.9 B | - | -18.52 % | $ 27.3 M | Britain |
 |
AbCellera Biologics
ABCL
|
299 M | $ 4.4 | - | $ 1.31 B | Canada |
 |
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 17.3 | - | $ 809 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.59 | - | $ 423 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
242 M | $ 91.99 | - | $ 22.2 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | USA |
 |
Compugen Ltd.
CGEN
|
93.4 M | $ 3.03 | - | $ 283 M | Israel |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 3.49 | - | $ 5.75 M | Israel |
 |
Aeterna Zentaris
AEZS
|
3.17 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
45.7 M | $ 0.73 | - | $ 33.4 M | Israel |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 21.57 | - | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
28.6 M | $ 9.24 | - | $ 264 M | USA |
 |
Esperion Therapeutics
ESPR
|
208 M | $ 3.12 | - | $ 649 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.9 M | $ 29.96 | - | $ 806 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Exelixis
EXEL
|
272 M | $ 51.1 | - | $ 13.9 B | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |